Companies see a commercial opportunity in creating new ways to administer drugs to patients – in space.

In a rare move, nonprofit organization Blood Cancer United is buying the remaining supplies of a discontinued investigational ...

Daraxonrasib doubles survival — a RAS‑targeting drug development breakthrough.

A clinical-stage innovator faces off against an established biotech powerhouse, each with distinct financials and risk ...

Pharma R&D is at a crossroads: the pressure to accelerate innovation, ensure compliance and manage fragmented data has never ...

Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by striking a broad pact that positions Pfizer to leverage Chi ...

As of March 2026, ELVN-001 produced meaningful responses in heavily pretreated patients, many of whom had already tried ...

Discover how quality-driven drug development and AI accelerate safer medicines, reduce risk, and improve patient outcomes.

The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...

Isomorphic Labs is developing a new engine for AI drug discovery ...

Big Pharma is pouring money into tech-devised treatments, but the verdict is out on whether they’ll actually work.

There has been much discussion recently about how artificial intelligence and machine learning (AI/ML) will revolutionize pharmaceutical research. Substantial progress has been made in the discovery ...